Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)

Sponsor
Samsung Medical Center
Study ID
NCT01054781
Phase
PHASE2
Status
Completed

Conditions

  • Diffuse Large B-cell Lymphoma (DLBCL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    1st cycle R+R-CHOP 2-8th cycle R-CHOP

Study Details

The purpose of this study is to evaluate the complete response (CR) rate after Intensified 1st cycle Rituximab plus 3rd cycles of R-CHOP in DLBCL

Key Dates

First listed
Jan 22, 2010
Start date
Jan 31, 2009
Status verified
Sep 2012
Primary completion
Nov 30, 2010

Study Design

Enrollment
91 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To evaluate the complete response (CR) rate after Intensified 1st cycle Rituximab plus 3rd cycles of R-CHOP in DLBCL and [ Time Frame: 12 months ]

Related Studies